Cargando…
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
The efficacy of ALK inhibitors in patients with ALK-mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human neuroblastoma...
Autores principales: | Wang, Hui Qin, Halilovic, Ensar, Li, Xiaoyan, Liang, Jinsheng, Cao, Yichen, Rakiec, Daniel P, Ruddy, David A, Jeay, Sebastien, Wuerthner, Jens U, Timple, Noelito, Kasibhatla, Shailaja, Li, Nanxin, Williams, Juliet A, Sellers, William R, Huang, Alan, Li, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435462/ https://www.ncbi.nlm.nih.gov/pubmed/28425916 http://dx.doi.org/10.7554/eLife.17137 |
Ejemplares similares
-
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017) -
ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018) -
The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
por: Miyazaki, Makoto, et al.
Publicado: (2018) -
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021) -
Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)